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Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with pro-
longed anemia caused by defective erythropoietin (Epo) production. We enrolled 34 recipients
of an allogeneic HSCT in three consecutive trials to determine the optimal utilization of re-








 7), rhEpo 1400 U/kg/week was given from day 1
until a hemoglobin (Hb) level of 10 g/dL was achieved, for a maximum of 60 days. In the sec-
ond trial, rhEpo 500 U/kg/week was given to achieve Hb levels of 13 to 14 g/dL in 13 anemic
patients with fatigue 56 to 1440 days after transplant. In the third trial, rhEpo was scheduled
to start on day 35 in 14 patients at a dose of 500 U/kg/week with the aim of achieving Hb levels




In trial 1, erythroid recovery to 1% reticulocytes and red blood cell transfusion inde-
pendence were faster, but the number of transfusions was not reduced compared to 10 con-
trols. Responses were brisk in trial 2, with transfusion independence achieved after a median
of 1 week in 12 of 13 patients, and 2-g Hb increments or Hb values of 11, 12, and 13 g/dL after
6, 7, 10, and 10 weeks, respectively. Transfusions were significantly reduced in the first month
of rhEpo therapy. In trial 3, transfusion independence was obtained after a median of 1 week
in 13 of 14 patients, and 2-g Hb increments or Hb values of 11, 12, and 13 g/dL after 3, 4, 6,
and 8 weeks, respectively. Transfusions rates were considerably reduced compared to the pre-
vious month in the same patients or compared to controls undergoing peripheral blood or




Anemia after allogeneic HSCT is exquisitely sensitive to rhEpo. The benefit is
minimal when it is given early post-transplant, as used in all trials to date. However, the rate of
major response is greater than 90% when rhEpo is started after day 35. These data provide the ba-
sis on which to conduct a prospective, randomized, placebo-controlled trial of rhEpo therapy
after allogeneic HSCT. © 2002 International Society for Experimental Hematology. Published
 
by Elsevier Science Inc.
 
Erythropoietin (Epo) is the critical regulatory factor of erythro-
poiesis, and recombinant human erythropoietin (rhEpo) has be-
come a well-established treatment for chronic renal failure pa-
tients. In these subjects, endogenous serum Epo levels are very
low [1], and administration of rhEpo to restore adequate levels
of the hormone permits correction of the anemia [2].
In patients with normal kidney function, serum Epo lev-
els increase exponentially when an anemia develops [1]. Af-
ter high-dose chemotherapy, serum Epo levels first rapidly
increase to disproportionately high levels for 1 to 3 weeks,
with peak values usually observed in the first week after the
conditioning regimen [3–14]. However, after allogeneic he-
matopoietic stem cell transplantation (HSCT), the Epo re-
sponse to anemia then generally becomes impaired, result-
ing in inappropriately low levels of Epo for the degree of
anemia and prolonged anemia [7–9,13–15]. This is specific
for allogeneic transplant because serum Epo levels remain
adequate throughout the post-transplant course in recipients
of autologous marrow or peripheral blood stem cell trans-
plant (PBSC) [6,7,10–15].
It is not surprising that rhEpo therapy has consistently
failed to accelerate erythropoietic recovery or to decrease
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transfusion requirements after autologous HSCT [16–22].
In contrast, clinical trials of rhEpo therapy after allogeneic
bone marrow transplantation (BMT) resulted in accelerated
erythroid engraftment and some reduction in transfusion re-
quirements [17,18,23–30]. However, in all of these studies,
the rhEpo dose used was very high (greater than 1000 U/kg/
week) and thus the cost was prohibitive. In addition, rhEpo
was only given from day 1 through days 30 to 55 or until
erythroid engraftment, a period when patients often are af-
flicted by serious toxic, infectious, or immunologic compli-
cations. This may explain why placebo-controlled trials
have shown little clinical benefit, including little reduction
in transfusion requirements, other than biologic signs of ac-
celerated erythropoiesis [18,27,28].
We report here our experience with three consecutive tri-
als of rhEpo therapy after allogeneic HSCT. In the first trial,
we administered Epo in the early post-transplant period but
failed to achieve significant clinical benefit. We then used
rhEpo in a manner more consistent with the pathophysiol-
ogy of erythropoiesis after allogeneic transplantation [14].
In the second trial, rhEpo was given to patients with persist-
ing anemia late after transplant, and excellent responses
were obtained with complete correction of hemoglobin (Hb)
values in the vast majority of the patients. In the third trial,
we examined whether starting rhEpo around day 35, when
the graft was well established and just before endogenous
Epo deficiency became prominent [14], would produce op-
timal responses. This approach proved very successful, and
responses were brisk and sustained. This study should form
the basis for a more rational use of rhEpo after allogeneic
HSCT and for the design of Phase III studies investigating
such clinical endpoints as transfusion requirements, iron






Thirty-four patients (22 males and 12 females; age 8 to 58 years,


















 15). The diagnoses were acute myeloid












 5), non-Hodgkin’s lym-


















 1). Their clinical characteristics are summarized in
Table 1. Conditioning before transplantation consisted of various









 7) total body irradiation. Graft-vs-host disease (GVHD) pro-









 19) short methotrexate. All patients were taking cyclosporine
when rhEpo was started. Single-donor platelet transfusions were









for packed red blood cell (RBC) transfusions decreased in recent
years at our institution so that patients in the first trial were trans-
fused when the hemoglobin level decreased below 9 g/dL while those
in the second and third trials received RBC transfusions when the
Hb was below 8 g/dL. Patients included in the first trial were com-
pared to 10 patients (3 MDS, 2 CML, 2 NHL, 1 AML, 1 SAA, and
1 neuroblastoma) undergoing an allogeneic PBSC transplant (9
HLA-identical and 1 one-mismatch sibling) in the same period but
not receiving rhEpo (control group). Patients in the third trial were
retrospectively compared to an historic group of 47 BMT patients
previously reported [14] as well as to 7 patients (2 MDS, 2 CML, 1
NHL, 1 AML, 1 SAA) of the PBSC control group with a follow-up








 7), rhEpo 1400 U/kg/week was given intrave-
nously (IV) on a daily basis from day 1 after peripheral blood
HSCT until an unsupported Hb level of 10 g/dL was achieved, for
a maximum of 60 days. The rhEpo (Eprex) was kindly provided by
Janssen-Cilag (Beerse, Belgium).




 13), rhEpo was given subcutaneously
(SC) three times per week to achieve Hb levels of 13 g/dL in pa-
tients who complained of fatigue and showed persisting anemia 56
to 1440 days after bone marrow or peripheral blood HSCT. The
dose was 500 U/kg/week, but three patients (no. 9, 10, and 17) with
anemia of renal failure received only one third to one half of that
dose and the dose was increased to 700 to 1000 U/kg/week in five
slowly responding patients. The rhEpo was kindly supplied by either
Janssen-Cilag or Roche (Neorecormon, Roche, Brussels, Belgium).




 14), rhEpo was scheduled to start on day
35 after bone marrow or peripheral blood HSCT at a dose of 500
U/kg/week (given SC in two divided doses) with the aim of
achieving and maintaining Hb levels of 13 g/dL. If there was an
active complication such as infection or GVHD on day 35, the in-
troduction of rhEpo was delayed until the complication resolved. If
the Hb had not increased by at least 1 g/dL after 1 month, the dose
was doubled (two patients). If no response was achieved after a to-
tal of 80 days of therapy, rhEpo was discontinued (one patient).
The rhEpo (Neorecormon) was kindly provided by Roche.
In the second and third trials, once the target Hb (13 g/dL) was
achieved, the dose of rhEpo was reduced so as to use the lowest
dose capable of maintaining Hb between 12 and 14 g/dL. No dose





Complete blood counts were determined in a Technicon H2 cell
counter (Bayer, Tarrytown, NJ, USA). Percentages of reticulo-
cytes were obtained by an automated cytofluorometric method
[31]. Serum Epo levels were measured by a commercially avail-
able radioimmunoassay (Incstar Corp., Stillwater, MN, USA).
Based on regression equations obtained in appropriate reference
subjects between hematocrit (Hct) on the one hand and log (Epo)
on the other, predicted log (Epo) values were derived for each Hct,
and O/P ratios of observed/predicted Epo values were calculated
[32]. Serum soluble transferrin receptor (sTfR), a quantitative
measure of total erythropoietic activity, was measured by a com-
mercially available ELISA (R&D, Minneapolis, MN, USA). Nor-




g/L. Serum iron, transferrin
saturation, and ferritin were measured by standard methods.
 
Evaluation of response to rhEpo
 
A major response (responder) was defined by an Hb increment
greater than 2 g/dL and achievement of an Hb level greater than 10
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g/dL without transfusion needs. The response was considered mi-
nor if only one of these criteria was fulfilled. In the second and
third trials, the response was considered as complete when Hb








-tests were used to compare bio-
logic variables in two groups or to compare baseline value with
later measurements in the same group of patients, respectively.
Welsh’s correction was used in case of unequal variance. Number
of transfusions in the same or in different groups of patients were





respectively. R correlation coefficients between two variables
were computed in least squares regression equations. Times to re-
sponse to rhEpo therapy as well as times to hematopoietic recovery
were studied by life-table analyses, and Wilcoxon rank tests were
used for comparisons between groups. Statistical analyses were







Compared to the control group, erythroid recovery was sig-
nificantly faster in the study group. Median time to 1%
reticulocytes was 12 days (range 10–25) in the study group









Neutrophil and platelet engraftments were not different.









stem cells Type of donor
ABO Rhesus
(Recipient/donor) Acute GVHD Chronic GVHD
Trial 1




























































































































































































































































































































































































































































 graft-vs-host disease; HLAid  HLA identical; M  male; MDS  myelodysplastic syndrome; NA  not
applicable because no rHuEpo was given before day 100 (aGVHD) or after day 100 (cGVHD); NHL  non-Hodgkin’s lymphoma; PBSC  peripheral blood
stem cells.
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independence within 30 days (Table 2). Two patients re-
mained transfusion dependent because of hemolysis and/or
bleeding. After excluding these two patients in the study
group as well as one patient in the control group who also
had severe bleeding, the median time to RBC transfusion in-
dependence was significantly shorter in the study group (21
days, range 7–29) than in the control group (40 days, range
21–110) (p  0.0007). However, the number of RBC trans-
fusions in the first 60 days post-transplant was not reduced:
median 12 (range 3–38) in the study group vs 14 (range 9–31)
in the control group (p  NS).
Second trial
Overall, responses were brisk (Table 3). Transfusion inde-
pendence was achieved after a median of 1 week (range 0–23)
in 12 (92%) of 13 patients. Median number of transfusions
per month decreased from 2 at baseline to 0 during months
1 (p  0.0020), 2 (p  0.0537; p  0.0020 after excluding
patient 16 who bled massively after responding well to rhEpo),
and 3 (p  0.0137; p  0.0039 after excluding patient 16)
of rhEpo therapy. Median time to an Hb increment of 2 g/dL
was 6 weeks, and Hb values of 11, 12, and 13 g/dL were
achieved after a median of 7, 10, and 10 weeks, respec-
tively. Complete responses were obtained in 11 (85%) of 13
patients, whose Hb increments ranged from 4.3 to 7.4 g/dL
(median 6.3) and peak Hb values from 13.5 to 15.6 g/dL.
Maintenance doses of 30 to 280 U/kg/week (median 135) were
capable of maintaining Hb levels between 12 and 14 g/dL for
periods up to 2 years. When rhEpo was discontinued, Hb de-
creased to a median of 9.9 g/dL within 3 months. One patient
had a minor response, with transfusion independence achieved
within 1 week and an Hb increment of 1.6 g/dL. However,
rhEpo was stopped prematurely after 35 days because the
patient developed grade IV acute GVHD with massive gas-
trointestinal bleeding. Finally, one patient with very poor
graft function (continuing platelet transfusions and granulocyte
colony-stimulating factor requirements), bleeding, and hemol-
ysis did not respond and remained transfusion dependent.
Third trial
Responses in these patients were excellent (Table 4). Trans-
fusion independence was achieved after 1 week in 13 (93%)
of 14 patients. Median number of transfusions per month
decreased from 3 at baseline to 0 in months 1 (p  0.0001),
2 (p  0.0002), and 3 (p  0.0081) of rhEpo therapy. Hb val-
ues of 11, 12, and 13 g/dL were achieved after a median of
4, 6, and 8 weeks, respectively. Median time to an Hb incre-
ment of 2 g/dL was 3 weeks. Thus, a complete response was
achieved in 12 and a major response in 1 of the 14 patients
(93%). Their Hb increments ranged from 3.8 to 10.3 g/dL





Reticulocytes (109/L) Hb (g/dL)
No. RBC 
transfusions
CommentsBaseline Peak Nadir Baseline Peak Nadir (days 1–60)
rhEpo group Day 0 On treatment
After 
treatment* Day 0 On treatment
After
treatment*
1 31† 19 39 25 9.5 Tx Tx 17 TTP, infection
2 18 9 294 76 9.7 10.6 9.1 3
3 60 7 341 121 9.5 11.9 Tx 12 Infection
4 60 23 211 59 10.9 10.8 9.6 15 Bleeding, VOD
5 31 24 328 NA 8.5 Tx Tx 38 Bleeding, AAHA, 
GVHD 
Infection
6 21 13 132 46 8.7 11.3 9.1 8
7 60 73 297 27 7.8 12.7 9.1 10 ATG
Median 31 19 294 53 9.5 11.3 9.1 12
Control group Day 0 Months 1–2 Months 3–5 Day 0 Months 1–2 Months 3–5
1 0 10 249 39 8.5 13.3 Tx 10
2 0 13 NA NA 9.3 NA NA 11
3 0 3 140 58 8.1 9.6 9.7 13
4 0 19 170 29 10.3 Tx Tx 12
5 0 26 ND NA 7.8 Tx NA 28 Infection
6 0 9 270 139 8.9 Tx 9.0 29 TTP
7 0 62 131 67 8.6 11.1 8.4 9
8 0 8 88 NA 8.4 Tx NA 15 VOD
9 0 10 164 NA 9.9 Tx NA 31 GVHD, bleeding
10 0 9 138 ND 8.9 Tx Tx 22 Infection
Median 0 10 152 58 8.7 11.1 9.0 14
*During the 3 months after cessation of rHuEpo. †rhEpo stopped because of hypertension and heart failure.
AAHA  acute alloimmune hemolytic anemia; ATG  antithymocyte globulins; NA  not applicable; ND  not done; TTP  thrombotic thrombocy-
topenic purpura; Tx  transfusion; VOD  veno-occlusive disease of the liver.
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(median 5.5) and peak Hb values from 12.3 to 17.1 g/dL.
Maintenance doses of 70 to 350 U/kg/week (median 150) were
used. The patient whose response was classified as major was
only treated for 10 weeks because she developed grade IV
acute GVHD with severe gastrointestinal bleeding and throm-
botic thrombocytopenic purpura. Patient 22 with very poor
graft function did not respond and remained transfusion depen-
dent. His bone marrow showed complete red cell and platelet
aplasia and was not modified after 80 days of rhEpo therapy.
Analysis of erythropoietic
response to rhEpo in trials 2 and 3
Figure 1 shows parameters of erythropoiesis and iron me-
tabolism in patients in trials 2 and 3 combined. Baseline Hb,
reticulocytes, sTfR, ferritin, and transferrin saturation were
similar in the two trials. Soluble TfR increased rapidly (me-
dian 3 weeks to double sTfR values) to reach a plateau after
3 to 4 weeks. It slowly decreased to baseline values when
rhEpo was discontinued. This expansion of erythropoietic
activity translated into more progressive Hb elevation over a
period of 10 weeks. Median time to an Hb increment of 2 g/dL
was 4 weeks, and it took only 9 weeks to reach an Hb of 13
g/dL. Time to an Hb increment of 2 g/dL was highly correlated
with time to reach an Hb of 13 g/dL (R  0.95, p  0.0001)
as well as with time to double sTfR levels (R  0.85, p 
0.0001). Reticulocytes initially increased but rapidly leveled
off (Fig. 1); this was particular true in trial 3 where reticulo-
cytes returned below baseline after 4 weeks in all but two
patients, while reticulocyte increases were more sustained in
trial 2. Transferrin saturation and ferritin decreased signifi-
cantly during rhEpo therapy and returned to baseline levels
thereafter (Fig. 1); this was particularly systematic in trial 3.
Recovery of erythropoiesis after transplantation in trial 3
was compared with that of historic controls undergoing ei-
ther PBSC or BM transplant without rhEpo (Fig. 2). Median
number of RBC transfusions between days 35 and 100 was
0 in the rhEpo group vs 4 in the PBSC group (p  0.0025)
and 10 in the BMT group (p  0.0003). Their transfusion
trigger was 8, 9, and 10 g/dL, respectively, explaining dif-
ferences in Hb levels in the early post-transplant period. Av-
erage sTfR levels remained at the lower end of normal val-
ues (3000 g/L) in patients not receiving rhEpo. However,
they rapidly increased above the upper normal limit (7000
g/L) with rhEpo therapy but progressively decreased when
the rhEpo dose was reduced. Hb values remained slightly
above 10 g/dL in patients not treated with rhEpo, whereas
they increased very rapidly in trial 3.
Discussion
Elevated serum Epo levels are observed transiently after in-
tensive conditioning regimens without concomitant changes

































8 55.5 1444 500 700 88† 7.1 14.5 10.0 2 0 0 0 Infection, bleeding, 
CRF, cGVHD
9 37.2 224 150 150 400 7.8 13.7 9.8 4 1 0 0 CRF
10 75.7 182 280 830 700 8.9 13.5 ND 6 3 2 6 PMF, CRF, cGVHD, 
infection
11 143.6 301 500 500 196 8.7 15.2 10.1 0 0 0 0 Infection
12 11.1 189 500 500 42† 8.0 14.3 9.1 1 0 0 0
13 40.9 105 500 870 215 8.6 15.6 11.6 4 0 0 0 PMF, infection
14 37.7 84 500 500 200 7.5 14.1 8.0 2 1 0 0 Pancreatitis, 
infection, surgery
15 38.1 126 500 500 140 8.9 15.2 9.9 0 0 0 0
16 97.1 56 500 500 35‡ 8.0 9.6 Tx 4 0 18‡ 6‡ aGVHD, bleeding, 
infection
17 ND 490 180 180 42† 9.2 13.5 10.6 0 0 0 0
18 38.4 154 500 1000 65 8.3 13.6 12.2 2 2 1 0 PRCA, infection
19 95.9 126 500 800 360 7.4 13.7 — 4 1 2 0
20 ND 63 500 1000 80‡ 7.6 Tx Tx 14 4 4 4 Dialysis, bleeding, 
TTP, infection, 
PMF
Median 48.2 154 500 500 — 8.0 13.7 9.9 2 0 0 0
*During the 3 months after cessation of rHuEpo.
†rhEpo stopped when Hb 14 g/dL and then later resumed. 
‡rhEpo stopped because of massive bleeding or no response.
aGVHD  acute graft-vs-host disease; cGVHD  chronic graft-vs-host disease; CRF  chronic renal failure; NA  not achieved; ND  not done. PMF 
poor marrow function; PRCA  pure red cell aplasia; sTfR  serum soluble transferrin receptor; TTP  thrombotic thrombocytopenic purpura; Tx  transfusion.
F. Baron et al./Experimental Hematology 30 (2002) 546–554 551
in hemoglobin [3–14]. Peak Epo values usually are ob-
served 7 days after transplant, at the time of the nadir of
erythropoietic activity. With marrow recovery, Epo levels
progressively return to an appropriate range, and the dura-
tion of this correction phase inversely correlates with the
speed of engraftment [11]. Thereafter, endogenous Epo re-
mains appropriate for the degree of anemia in autologous
transplants [6,7,10–15] but rapidly becomes inadequately
low in allogeneic transplants [7–9,13–15]. This defect in
Epo production is attributed to the use of cyclosporin A
[33,34], which inhibits Epo secretion [35], but acute GVHD
[8,13–15] or cytomegalovirus infection [13,15] also con-
tribute. Therefore, the development of erythropoiesis after
autologous transplantation is limited by the availability of
Epo receptor-bearing erythroid precursors rather than the
supply of Epo, whereas after allogeneic HSCT erythropoie-
tic recovery is impaired because Epo levels remain inade-
quate for prolonged periods of time [14].
Previous trials of rhEpo therapy after allogeneic HSCT have
not considered this pathophysiology of erythropoiesis. All
studies to date administered very high doses of IV rhEpo
starting on day 1 and continuing for 1 to 2 months or until
erythroid engraftment. Pilot trials showed accelerated eryth-
ropoiesis with increased reticulocyte, sTfR, and/or hemat-
ocrit values, as well as a reduction in RBC transfusions
compared to historic controls [17,23–26,29,30]. Some even
reported an impact on platelet engraftment and/or platelet
transfusions [17,25,26,29]. However, larger placebo-con-
trolled studies with rhEpo doses 900 to 1400 U/kg/week
confirmed the potential for accelerating red cell but not
platelet recovery [18,27,28]. A reduction in RBC transfu-
sions was observed in the smallest trial [28], not in the sec-
ond one [27] and only between days 20 and 40 (not overall),
and particularly in patients with severe acute GVHD in the
third trial [18]. Our first trial presented here, even though it
consisted of only small numbers of patients, is in line with
these findings. Therefore, soaking patients with huge doses
of rhEpo at a time when the erythroid marrow has not devel-
oped a sufficient number of erythroid precursors to respond
and when many intercurrent complications such has organ
Table 4. Response to rhEpo treatment in the third trial
No.
rhEpo treatment

















treatment* Baseline Month 1 Month 2 Month 3
21 29.1 35 500 500 40§ 9.1 12.9 — 4 0 0 —
22 714.6 35 500 1000 84‡ 7.4 Tx Tx 7 7 8 10 PMF
23 20.3 42 500 500 140 8.5 14.6 12.0 2 0 0 0
24 34.3 38 500 500 88§ 8.2 14.1 Tx 2 0 0 0 Infection, 
relapse, 
surgery
25 42.7 49 500 500 133 8.7 13.9 10.0 1 0 0 0 Infection
26 56.8 35 500 500 42† 8.4 13.9 9.9 3 0 0 0
27 58.1 35 500 1000 80‡ 8.1 12.3 Tx 4 0 0 1‡ aGVHD, 
bleeding,
 TTP
28 23.8 40 500 500 56 9.4 15.0 10.3 1 0 0 0 Infection
29 32.5 35 500 500 290 8.3 14.3 9.4 3 1 0 0 Infection, 
bleeding
30 100.6 35 500 500 91† 6.8 17.1 8.4 2 1 0 0 CMV, 
GVHD, 
infection




32 29.5 39 500 500 55§ 9.2 14.1 Tx 2 0 0 — Infection, 
relapse
33 41.8 38 500 500 172 9.4 14.0 12.0 2 0 0 0 CMV
34 233.4 35 500 500 98 7.6 15.1 10.0 8 0 0 0 Infection
Median 38.1 35 500 500 — 8.4 14.1 — 3 0 0 0
*During the 3 months after cessation of rhEpo.
†rhEpo stopped when Hb 14 g/dL and then later resumed. ‡rhEpo stopped because of massive bleeding or no response.
§rhEpo stopped at time of death or relapse.
aGVDHD  acute graft-vs-host disease; NA  not achieved; ND  not done; PMF  poor marrow function; sTfR  serum soluble transferrin receptor;
TTP  thrombotic thrombocytopenic purpura; Tx  transfusion.
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toxicity, infection, acute GVHD, and bleeding may blunt re-
sponse may not be the best way to use rhEpo after an alloge-
neic transplant.
We took a more physiologic approach in the second trial
by providing rhEpo to patients with anemia persisting 56 to
1440 days after transplantation. This proved to be a very ef-
ficient strategy, with transfusion independence and com-
plete correction of Hb achieved in 92% and 85% of patients,
respectively. A considerable reduction in transfusions al-
ready was apparent in the first month of therapy with me-
dian doses of 500 U/kg/week, which are 2 to 3 times lower
than doses used in previous transplant trials but similar to
doses used in cancer-associated anemia. However, the rate
and quality of response were far superior to those achieved
in the anemia of cancer where the proportion of patients in-
creasing Hb by 2 g/dL is 40 to 60% [36–39]; transfusions
are not decreased before the second month [37]; and it typi-
cally takes 4 weeks [40] and 6 to 16 weeks [38,39] to in-
crease Hb by 1 and 2 g/dL, respectively. Average mainte-
nance doses were 135 U/kg/week for up to 2 years. We took
it a step further in the third trial by scheduling the start of
rhEpo at day 35. Responses were even faster, with transfu-
sion independence achieved after 1 week in 90% of patients
and complete correction of the anemia after a median of 8
weeks in 80%. With the limitations of differences in type of
transplant and transfusion trigger, the transfusion rate was
considerably reduced compared to historic controls. Median
doses of 150 U/kg/week were used to maintain target Hb
values.
The expansion of erythropoietic activity was consider-
able, reaching sTfR values well above the normal range in
the majority of the patients, a feature never observed in allo-
geneic transplant recipients not receiving rhEpo (Figs. 1 and
2). This expansion reached its maximum even faster than in
renal failure patients (who also received lower doses of
rhEpo) [41]. When rhEpo therapy was discontinued, eryth-
ropoiesis rapidly declined and almost all patients lost sev-
eral grams of Hb and again became anemic (Tables 3 and
4). This clearly illustrates that post-transplant anemia is Epo
dependent and exquisitely responds to substitutive therapy.
Hb increases correlated with the expansion of erythropoietic
activity and usually occurred rapidly. Other than one patient
in both trials 2 and 3 who were not fully evaluable because
of severe gastrointestinal bleeding and early death due to
acute GVHD, only two patients did not fully respond to
rhEpo. Although we did not provide any iron supplements,
transferrin saturation rarely decreased below 20% (Fig. 1);
thus, functional iron deficiency [42] was not an issue be-
cause most patients had very large iron stores from previous
transfusions.
Responses were particularly fast when rhEpo was started
around day 35 post-transplant. This is not surprising because
this is a period when (erythropoietic) marrow recovery is in
full motion before cyclosporine-induced Epo deficiency has
had enough time to reduce the pool of erythroid precursors
[14]. This timing appears to be optimal because it provides
large amounts of Epo just when the erythroid marrow is most
susceptible to respond. However, intercurrent complications
may blunt or temporarily abort responses; therefore it is
preferable to start rhEpo only when major problems such as
severe infections and active bleeding or hemolysis are well on
the way to resolution.
Our study has the limitations of nonrandomization and
small patient numbers. However, the results are impressive
and suggest that allogeneic HSCT is associated with the
Figure 1. Erythropoietic parameters since start of rHuEpo therapy in trials
2 and 3 combined. The rHuEpo was given for varying periods of time
(minimum 5 weeks). TS  transferrin saturation. p Values are given for
comparisons with baseline: *p  0.05, **p  0.01, ***p  0.001.
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best response rate to rhEpo outside the setting of uremia
[43]. Our data set the stage for more rational use of rhEpo after
allogeneic HSCT and should renew interest in Epo therapy
after the relative disappointment with previous trials targeting
initial erythroid recovery rather than the more physiologically
appropriate period that follows engraftment. Prospective, ran-
domized, placebo-controlled trials should investigate clinical
endpoints previously shown to be improved by rhEpo therapy
in other settings, such as transfusion requirements and quality
of life.
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